Skip to content
Screener

aTyr Pharma ATYR Q3 2025 earnings

Reported November 6, 2025 · Before market open

Revenue$190.0KBeat by $170.0K
EPS-$0.26Miss by $0.06
Revenue estimate$20.0K
EPS estimate-$0.20

Next report

Nov 5, 2026 (in 3 months)
Revenue estimate$2.5M
EPS estimate-$0.17

Financials

Q3 2025

Income statement

See full
Revenue$190.0K—
Operating income-$26.7M-47.4%
Net income-$25.7M-49.2%
EPS (diluted)-$0.26-13.0%

Balance sheet

See full
Cash & equivalents$6.2M-46.3%
Total debt$13.0M-7.9%
Total equity$80.2M+22.8%
Total assets$106.7M+16.4%

Cash flow

See full
Operating cash flow-$20.5M-55.6%
CapEx$37.0K+147%
Free cash flow-$20.5M-55.7%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$70.69M-44.4%
Enterprise value$77.53M-40.3%
P/S372×-169×

Profitability

See full
Operating margin-41,395.3%+31,159pp
Net margin-39,537.9%+33,138pp
FCF margin-33,154.2%+6,364pp

Returns & leverage

See full
Return on equity-103.2%+49.5pp
Debt / equity0.2×-0.1×
Current ratio5.9×+0.5×

FAQ

When did aTyr Pharma report Q3 2025 earnings?
aTyr Pharma (ATYR) reported Q3 2025 earnings on November 6, 2025 before market open.
What were aTyr Pharma's Q3 2025 revenue and EPS?
aTyr Pharma reported revenue of $190.0K and eps of $-0.26 for Q3 2025.
Did aTyr Pharma beat estimates in Q3 2025?
Revenue beat the consensus estimate of $20.0K by $170.0K. EPS missed the consensus estimate of $-0.20 by $0.06.
How did aTyr Pharma's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 13.0% from $-0.23.
Where can I find aTyr Pharma's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-269486) and the 10-Q periodic report (0001193125-25-269587) directly on SEC EDGAR. The filing index links above go to sec.gov.